Kerry’s primary focus is patent drafting, prosecution, opposition and appeals before the European Patent Office but he also has extensive experience in all phases of foreign patent prosecution. He also provides FTO/infringement advice.
He undertakes work in a wide variety of technology areas including pharmaceuticals, biologicals, biochemistry, microbiology, cell and molecular biology, immunology and diagnostics including sequencing technologies.
Kerry has a particular interest in food technology, including alt proteins, fermentation, cultured meat and cellular agriculture, food ingredients, food feed and food enzymology, advising a variety of companies at various stages of development on IP strategies to attract funding or IP due diligence in preparing for acquisition, and advising on proactive attacking or defensive strategies in relation to third party IP.
Kerry acts for a wide range of clients including start-ups and investors, research institutions, universities and spin-outs, mid-size companies and international corporations.
Kerry works with private equity and venture capital investors to assess and mitigate IP risks associated with an investment. Kerry particularly enjoys working with investee companies to develop IP strategies which support the business plan and to secure commercially relevant IP whether that be to secure funding or increase growth and market share.
Molecular and Cellular Biochemistry, University of Oxford
Certificate in Intellectual Property Law, University of London
Kerry is listed as a "Key Lawyer" in Legal 500.
"Kerry Rees delivers excellent advice on complicated IP issues. He is flexible and technically competent. He is super smart and highly responsive, making him a definite go-to for all things IP."
December 6th 2022
October 6th 2022
September 22nd 2022
May 18th 2021
December 2nd 2020
November 20th 2020
September 11th 2020
September 2nd 2020
Kerry mentors our trainee attorneys in preparation for their professional examinations.
Kerry is an active participant in HGF’s community outreach programme.
The European Patent Office (EPO) has announced that revised Official Fees will apply to payments made on or after Monday 1st April 2024. The majority of fees will increase by …Read article
HGF are proud Event Partners of CAR-TCR Europe, which is due to go ahead from 27th – 29th February at ExCeL, Royal Victoria Dock in London. This is the European hub …Event details
Porter’s Five Forces model  is just one example of a convenient model for exploring and understanding the forces at play in a competitive marketplace. Michael Porter’s Five Forces model …Read article
In an unprecedented move, the MHRA has approved a CRISPR gene editing therapy ‘Casgevy’ for the treatment of sickle cell disease and beta-thalassaemia in patients with recurrent vaso-occlusive crises. The Casgevy …Read article
HGF is pleased to invite you to our upcoming German-language seminar on “Invention and patent searches in public databases” in Salzburg and Dresden. The seminar will showcase how public databases …Event details
“Medical devices and bioinformatics / AI diagnostic feedback – law and practice in Europe and Japan” The EPC does not allow ‘medical use’ claims for medial devices. So how do …Event details
A patent is a legal right that enables the patent holder to prevent others from making and using their invention in the country where the patent is granted. To many …Read article
Order of the classifications listed on the front of a patent and why it matters? On 1 June 2023, ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE lodged a statement of revocation of …Read article
If you would like to discuss how HGF could help you, contact one of our IP specialists.